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Purpose: Following the discovery of the carcinogenicity of phenolphthalein and the 
subsequent ban of this compound in several countries this study was undertaken to develop 
compounded formulations of laxative products containing the stimulant laxatives sennosides 
A and B.  
Methods: DSC and HPLC analysis was used to determine the compatibility of sennosides 
with commonly used excipients before compounding capsules, tablets and effervescent 
tablets containing sennosides A & B. The physical and chemical stability and release 
properties of these dosage forms were determined for 12 weeks at increased temperature 
and relative humidity.  
Results: Sennosides A & B were compatible with a wide variety of powdered excipients. 
However, these were incompatible with propyl paraben, sodium carbonate, stearic acid, citric 
acid, PEG, and sugar derivatives such as lactose, glucose and sorbitol when granulated with 
water. Not withstanding these interactions, it was possible to compound simple capsule, tablet 
and even an effervescent tablet formulations containing sennosides A & B that complied with 
pharmacopeial specifications. However, all these formulations were sensitive to moisture 
because when stored at increased temperature and relative humidity, disintegration times 
increased and dissolution rates decreased.  
Conclusion: Based on compatibility and stability studies simple, stable and elegant solid 
dosage forms containing sennosides A & B were compounded that can be used to replace 
phenolphthalein in a variety of solid dosage forms. 
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Introduction 
Until recently, the laxative most frequently 
used because of its fast and efficient effect 
was phenolphthalein1. Phenolphthalein is a 
coal tar derivative synthesised in the 1870s 
and initially used as an acid-base indicator. 
In 1900, Hungarian pharmacologist Zoltan 
Vamossy was entrusted with evaluating the 
toxicity of this compound and he discovered 
that phenolphthalein was a laxative1. 
Laxatives are classified as bulk, osmotic, 
stool softening, lubricant and stimulant 
laxatives. Phenolphthalein is classified as a 
stimulant laxative2,3. The stimulant laxatives 
increase the propulsive peristaltic activity of 
the intestine by local irritation of the mucosa 
or by a more selective action on the 
intramural nerve plexus of intestinal smooth 
muscle; thus increasing motility4. 
Since its introduction as a cheap laxative, 
phenolphthalein has always been seen as a 
safe drug because only a few cases have 
been reported where excessive ingestation 
of phenolphthalein caused adverse effects 
including an urticarial rash due to ‘toxic 
epidermal necrolysis’ (TEN), erythema 
multiforme, Stevens Johnson syndrome and 
abdominal pain5,6. However, recently 
phenolphthalein has proven to be a concern, 
starting in the USA where the National 
Cancer Institute of America nominated 
phenolphthalein for study because of its 
widespread use and lack of adequate testing 
for carcinogenety. The National Cancer 
Institute of the USA performed a study on 
F344/N rats and B6C3F1 mice, giving them 
98-99 % pure phenolphthalein with their 
diet7,8. The rats and mice were studied after 
14 days, 13 weeks and 2 years.  
The 14-day and 13-week studies did not 
show any difference in the exposed groups 
of rats and mice, from those of the controls. 
Under the conditions of the 2-year feed 
studies there was clear evidence of 
carcinogenic activity of phenolphthalein in 
the male F344/N rats based on increased 
incidences of benign pheochromocytoma of 
the adrenal medulla and of the renal tubule 
adenomas. Some evidence of carcinogenic 
activity of phenolphthalein was found in the 
female F344/N rats because of the increased 
incidences of benign pheochromocytomas of 
the adrenal medulla. There was clear 
evidence of carcinogenic activity of 
phenolphthalein in the male B6C3F1 mice 
based on increased incidences of histiocytic 
sarcomas and of malignant lymphomas of 
thymic origin. In the female B6C3F1 mice 
there was clear evidence of carcinogenic 
activity of phenolphthalein based on 
increased incidences of histolytic sarcomas, 
malignant lymphomas of all types, 
lymphomas of thymic origin and benign sex-
cords stromal tumours of the ovary7,8. In 
another study it was discovered that there 
was a significant reduction in fertility in Swiss 
CD-1 mice, with a decrease in the number of 
litters per fertile pair and at terminal 
necroscopy male kidneys were enlarged and 
right epididymis and testis weights were 
significantly lower than controls. In males the 
incidence of abnormal sperm was also 
increased9. 
When the findings of these studies were 
made available the Food and Drug 
Administration in the USA on 29 January 
1999 issued a final rule on the use of 
phenolphthalein as an OTC laxative 
proposing a ban of all OTC laxatives 
containing phenolphthalein10,11. They claim it 
to be unsafe and misbranded and to be 
classified as an ingredient (Table 1) which 
cannot be regarded as safe and effective. 
This meant that manufacturers of 
phenolphthalein products then had to seek 
for a substitute for this popular laxative that 
now proved to be unsafe. The decision of the 
FDA has spilled over to other countries such 
as South Africa where phenolphthalein was 
banned on 22 February 200212. Prior to the 
ban as many as 17 products in South Africa 
contained phenolphthalein in various dosage 
forms such as tablets, capsules, liquids, gels 
and granules. These products would now 
have to be reformulated or removed from the 
market leaving a huge gap in the range of 
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cheap laxatives currently available. 
To help with the reformulation and 
replacement process, this study reports the 
formulation and stability of several solid-
dosage forms containing sennosides A and 
B (Senna). This laxative was chosen as an 
alternative because it falls within the same 
category of stimulant laxatives (Table 1) as 
phenolphthalein. Senna is also widely used 
and still regarded as safe and effective. 
Materials and Methods 
Materials 
In this study calcium sennosides A and B 
obtained from Ciba Geigy (Johannesburg, 
South Africa) were used. Chemically, this 
compound belongs to the group of glycoside-
linked anthraquinones and consists 
principally of two stereoisomers, namely 
sennoside A and sennoside B. The following 
excipients were used: Lactose (Tablettose, 
Meggle Excipients, Germany and Ludipress, 
BASF, South Africa), dibasic calcium 
phosphate dihydrate, (Emcompress, JRS 
Pharma LP, New York, USA), mannitol, 
microcrystalline cellulose (Avicel pH 101 & 
PH200, FMC Corporation, Ireland), 
pregelatinised starch (Starch 1500, 
Colorcon, USA), polyvinyl pyrrolidone 
(Kollidon 25, BASF), gelatin, glucose, 
polyethylene glycol 6000 (BASF), 
magnesium stearate, stearic acid, sorbitol, 
sodium bicarbonate, sodium carbonate, citric 
acid, and propyl paraben. All other solvents 
and chemicals used were of analytical grade 
and were used as received. 
Drug-Excipient Compatibility Studies 
Assessment of possible incompatibilities 
between an active drug substance and 
different excipients forms an important part 
of the preformulation stage during the 
development of a solid dosage form13. 
Successful compatibility studies require a 
good experimental design that furnishes the 
required information with the minimum of 
experimental effort. In this study 1:1 w/w 
samples of active and excipients were 
intimately mixed in a mortar with a pestle, 
either as dry powders or powders wetted 
with a small amount of water. The granulated 
samples were dried in an oven for 1 hour at 
60°C. These mixtures were then evaluated 
by differential scanning calorimetry (DSC) 
and high performance liquid chromatography 
(HPLC). 
Table 1: OTC status (United States), site of action, and recommended adult dosing of stimulant 
laxatives2,3. 
 
Category/Name Site of action Recommended adult daily 
dose 
Current OTC status 
Diphenylmethanes    
phenolphthalein  Do not recommend Category II 
bisacodyl  Colon 10-15 mg PO, 10 mg PR Category III 
Anthraquinones    
sennosides  Colon 15-35 mg Category II 
aloe  Colon 30-60 mg Category II 
cascara  Colon 2-5 ml Category II 
Surface-acting agents    
docusate  GI tract 100-300 mg Category I 
Ricinoleic Acid    
castor oil  Small intestine 15-60 ml PO Category I 
PO = per mouth; PR = per rectum; OTC = Over the counter 
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For DSC analysis samples with a mass 
between 2-4 mg were measured and 
crimped into aluminium seal pans. The 
sealed pans were placed in a Shimadzu 
DSC-50 Differential Scanning Calorimeter 
(Shimadzu, Japan). The sealed pans were 
heated at a heating rate of 10 °C/min and 
under a nitrogen purge with a flow rate of 30 
ml/min. DSC thermograms of the 1:1 w/w 
mixtures were compared to the thermograms 
of the individual excipients and sennosides. 
The criteria used to determine if an excipient 
was incompatible with the sennosides were 
the following: the peaks have either 
elongated or broadened, extra peaks 
occurred, peaks shifted or disappeared, or 
there was a shift in melting points of 
endotherms and exotherms as result of 
thermal behavior. These changes in peaks 
are due to incompatibility with the 
sennosides. 
For HPLC analysis of the sennosides the 
method described by Muffat et al. was used 
with a few alterations14. The instrument used 
was a HP1050 series HPLC 
equipped with a HP1050 
quaternary gradient pump, 
HP1050 autosampler, 
HP1050 diode array 
detector and Chemstation 
data acquisition and 
analysis software (Agilent, 
California, USA). The 
column used was a Luna 
C18-2 µm column, 250 x 4.6 
mm (Phenomenex, 
California, USA); mobile 
phase: methanol: 
acetonitrile: buffer 
(240:160:600 v/v/v); buffer: 
0.01 M tetra n-butyl 
ammonium iodide (3.68 g/l) 
in water, pH adjusted to 7 
using NH4OH; flow rate: 1.0 
ml/min; retention time: 9.4 
min and 10.9 min for the 2 
sennoside peaks (Figure 1); 
injection volume: 10 µl; 
detection: UV at 270 nm. 
Formulation of Solid Dosage Forms 
In this study capsules, tablets and 
effervescent granules containing sennosides 
were prepared using those excipients that 
were compatible with the active ingredient. 
To prepare capsules the ingredients were 
weighed and mixed together in a Turbula 
mixer (WA Bachofen, Switzerland) for 5 min. 
A hand-operated capsule filling machine was 
used to fill the mixtures into size 0 capsules. 
Table 2 shows the formulae used to 
manufacture the sennoside capsules.  
One directly compressed and one wet 
granulated tablet formula, Table 3, were 
made for stability purposes after several trial 
and error batches of a number of different 
formulas were made. For direct 
compression, the ingredients were weighed 
and mixed together in the Turbula mixer for 5 
min. The mixture was then compressed into 
tablets at the predetermined mass and 

















R Squared 0.9997 Lower 95% Upper 95% 
Intercept 13.902 -3.731 31.536 







Figure 1: HPLC Chromatograms of Sennosides A and B. 
Parameters for linearity are shown on the figure. Retention time: 
Sennoside B = 9.4 min, Sennoside A = 10.9 min; Number of 
theoretical plates (N): Sennoside B = 7527 plates/column, 
Sennoside A = 6298 plates/column (Tangent method); USP tailing 
factor (T): Sennoside B = 0.95, Sennoside A = 1.04; Capacity factor 
(k’): Sennoside B = 1.68, Sennoside A = 2.09; Resolution between 
peaks: 2.98.15,16 
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sennosides, PVP, Avicel and Emcompress 
were weighed and mixed together in a 
mortar with a pestle. Distilled water was 
added and mixed until the blended powders 
were moistened sufficiently. The wet mass 
was spread out on drying trays and dried in 
an oven at 60°C. After drying, the granules 
were passed through a 2 mm mesh screen, 
magnesium stearate was added and the 
mixture was then mixed in a Turbula mixer 
for 5 min. The granules were then 
compressed into tablets at the 
predetermined mass and hardness.  
To prepare the effervescent tablets only 
water-soluble excipients were used as 
shown in Table 5. To prepare the mixture for 
compression, citric acid, sodium bicarbonate, 
sodium cyclamate, sodium saccharin, PVP 
and sennosides were weighed and mixed 
together with a mortar and pestle. Water was 
added and the mixture was mixed vigorously 
while effervescence occurred. The wetted 
mixture was sieved through a 2 mm mesh 
Table 2: DSC and HPLC results for the compatibility assessment of mixtures of sennosides and commonly 
used solid dosage form excipients 
 
Excipient DSC HPLC 
 Dry Granulated Dry mix Granulated mix 
 Mix Mix Assay (%) Interaction Assay (%) Interaction 
Emcompress - - 98.8±4.1 - 99.9±7.8 - 
Gelatin - - 94.3±4.9 - 97.8±0.6 - 
Lactose - - 104.1±9.1 - 88.6±2.5 + 
Ludipress - - 94.1±3.1 - 87.3±5.3 + 
Tablettose - + 94.4±9.4 - 81.2±4.3 + 
Glucose - + 92.9±3.16 - 88.9±2.1 + 
Sorbitol - + 102.5±6.2 - 84.2±3.8 + 
Mannitol - - 100.6±1.8 - 97.2±2.3 - 
Starch - - 106.3±4.7 - 89.8±2.66 - 
Starch 1500 - - 99.6±6.2 - 96.4±5.3 - 
PEG 6000 - - 97.5±0.9 - 72.0±8.1 + 
PVP - - 97.9±0.8 - 82.0±2.8 - 
Na2CO3 - + 85.3±5.5 - 61.7±0.8 + 
NaHCO3 - - 106.1±3.5 - 94.8±8.23 - 
Mg Stearate - - 99.6±1.3 - 94.2±8.0 - 
Avicel - - 106.4±1.8 - 93.9±7.4 - 
Citric Acid - - 101.3±13.4 - 34.6±16.6 + 
Stearic Acid - + 91.8±10.5 - 71.6±10.3 + 
Propyl Paraben - - 101.1±5.2 - 82.8±4.1 + 
- = No interaction; + = Interaction 
Table 3: Composition of the two capsule formulations containing 15 mg sennosides A and B 
per capsule 
 
Formulation 1 (% w/w) Formulation 2 (% w/w) Function 
Sennoside 4 Sennoside 2.5 Active ingredient 
Avicel PH101 95 Starch 1500 97 Filler/ diluent 
Mg Stearate 1 Mg Stearate 0.5 Lubricant 
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and dried at 60 ºC. The flavor, sodium 
carbonate and PEG 6000 were weighed and 
added to the wetted mixture after it had been 
cooled. The powder was mixed thoroughly 
and again sieved through the 2 mm mesh 
sieve. The mixture was then compressed 
into tablets at the predetermined mass and 
hardness. 
Stability Testing of Solid Dosage Forms 
Tablets, capsules and effervescent tablets 
were stored at 25 °C (60 % Relative 
Humidity (RH)), 30 °C (60 % RH) and 40 °C 
(75 % RH). They were tested at 0 (initial), 6 
and 12 weeks. The following tests were used 
to evaluate the tablets: hardness, friability, 
assay, uniformity (mass, thickness and 
diameter), loss on drying, disintegration and 
dissolution. For the capsules the following 
tests were used: uniformity (mass of capsule 
and empty capsule mass), assay, 
disintegration, loss on drying and dissolution. 
The hardness of 20 tablets of each formula 
was measured with a hardness tester 
(Pharma Test, type PTB 103, Switzerland).  
The friability of the tablets gives a good 
indication of how they will withstand 
transport and handling. Twenty tablets were 
weighed and were put into the Roche 
friabilator for 4 min after the tablets were 
dusted and weighed again. The percentage 
weight loss was then determined. 
For the assay test standards were made 
equivalent to the amount of sennosides in 
the capsule, tablet or effervescent tablet. 
The samples consisted of powdered tablets 
or capsules equivalent to the mass of one 
tablet or capsule. The amount of sennosides 
in the standard and samples were then 
determined using HPLC. The USP states 
that the tablets should have 90 – 110% of 
the labelled amount of sennosides15. The 
same limits were used for the capsules or 
effervescent tablets since there is no 
mention of sennoside capsules or 
effervescent tablets in the USP. To 
determine the weight uniformity twenty 
tablets and capsules were weighed 
individually and their mean weight was 
determined. The thickness and diameter 
were determined with a Pharma Test, type 
PTB 103, Switzerland. Not more than two 
tablets or capsules are permitted to differ 
from the mean by a percentage greater than 
stated in British Pharmacopoeia14. For the 
capsules, individual capsules were weighed 
and the contents of the capsule emptied. 
The capsules were then washed with ethanol 
and left to dry. The empty capsules were 
then weighed. The difference in weight 
showed the weight of the capsules. To 
measure the loss on drying, about 1 g of the 
capsule contents and powdered tablets was 
weighed. The capsule contents or powdered 
tablets were put in an oven and dried to 
constant weight at 105 °C. They were 
allowed to cool and were then weighed 
again. The percentage weight loss was 
determined and should not exceed 6 % 
according to the BP16. In addition the 
disintegration time of six tablets and 
capsules were also measured using the 
standard method of the USP15. 
Method 1 of the USP (basket method) was 
used to determine the dissolution rate of the 
solid dosage forms. Before dissolution 
testing each tablet or capsule was weighed. 
The dissolution medium was 900 ml water 
which was maintained at 37 °C. A basket 
was used to hold the tablet or capsule which 
rotated at 100 rpm. The samples were 
obtained with a pipette, followed by 
replacement with an equal volume of 
dissolution medium. The samples were 
analysed using HPLC. The dissolution rate 
was not measured for the effervescent 
tablets but the effervescence time was 
measured by placing the tablet in 250 ml 
distilled water at ∼20ºC and recording the 
time when no more gas bubbles evolved 
from the tablet. The pH was also measured 
after the tablet had completely dissolved. 
Statistical Evaluation of Data 
Statistical analysis was performed to 
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determine significant differences at a 
95% confidence level (p<0.05) (Microsoft 
Excel, Microsoft Corporation, USA). 
Results and Discussion 
Excipients for the formulation of 
sennoside tablets, capsules and 
effervescent tablets were chosen from 
the Handbook of Pharmaceutical 
excipients17. Examples were chosen from 
each of the major excipient categories 
based on cost, availability, and 
acceptability. 
Compatibility between Sennosides and 
Excipients 
A summary of DSC results for the 
evaluation of the compatibility between 
the sennosides and commonly used solid 
dosage form excipients are given in 
Table 2. A (-) indicates no interaction 
between sennosides and excipient and a 
(+) indicates that there was an 
interaction. In the dry form no interactions 
occurred. In the wet granulated samples 
however five interactions were 
discovered because glucose, sodium 
carbonate, sorbitol, stearic acid and 
lactose (Ludipress® and Tablettose®) 
showed incompatibilities. These 
interactions were derived from the 
disappearance of the dehydration, 72 °C, 
and melting, 276 °C, peaks of the 
sennosides (Figure 2) in the mixtures. The 
glucose-sennoside mixture  in a wet 
granulated sample showed only one peak at 
183°C, indicating the disappearance of the 
glucose and sennosides peaks. Pure sodium 
carbonate showed one peak at 87°C (Figure 
2) which shifted to 109°C in the wet 
granulated sample. Sorbitol showed peaks at 
96 °C (Figure 1) which moved to 422 °C and 
308 °C in the mixture. Stearic acid showed 
one peak at 56 °C, but an extra peak 
appeared in the wet granulated sample at 74 
°C. Tablettose showed peaks at 146 °C and 
at 213 °C, typical for lactose monohydrate 
dehydration and melting respectively. The 
wet granulated lactose samples showed only 
one peak at 192 °C. 
HPLC analysis was used to confirm the 
incompatibilities obtained by DSC. The 
chromatogram of the sennosides (Figure 1), 
showed a peak at 9 min (sennoside B) and a 
peak at 11 min (sennoside A). Interference 
by individual excipients with the HPLC of the 
sennosides was tested by injecting samples 
of the pure excipients. None of the excipients 
tested had retention times close to that of the 
sennosides. The results listed in Table 2 
confirm that there was no interaction 
between the sennosides and excipients in 
the dry state. However, in the granulated 






















Figure 2: DSC Thermograms: (a) Sennosides; (b) 
sorbitol; (c) 1:1 sorbitol-sennoside mixture; (d) 
sodium carbonate; (e) 1:1 sodium carbonate-
sennoside mixture; (f) Tablettose (lactose); (g) 1:1 
lactose-sennoside mixture; (h) glucose; (i) 1:1 
glucose-sennoside mixture; (j) stearic acid; (k) 1:1 
stearic acid-sennoside mixture. The arrow indicates 
the direction of endothermic processes 
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samples statistical analysis showed that 
propyl paraben, sodium carbonate, stearic 
acid, citric acid, PEG, lactose, glucose and 
sorbitol were incompatible with the 
sennosides. Especially, HPLC showed that 
the recovery for sodium carbonate (62 %), 
stearic acid (72 %) and citric acid (35 %) was 
very low in the wet granulated mixtures.  
Formulation of Sennoside Capsules 
Hard gelatin capsule is a convenient, 
consumable pharmaceutical package that 
can be used to produce stable, uniform unit-
dose forms because it is robust and can be 
filled with a variety of materials to yield 
stable products. In Table 3 the composition 
of two capsule formulations containing 15 
mg sennoside and filled into size 0 capsules 
with a capacity of ~ 0.3-0.7 g, depending on 
the density of the powders, are listed. Due to 
lower density, larger particle size and higher 
porosity of microcrystalline cellulose 
compared to Starch 1500, the capsule fill 
mass of Formula 1 (± 360 mg) was less than 
that of Formula 2 (± 575 mg). 
Using the criteria set by the BP16, the 
average weight of capsules weighing more 
than 250 mg cannot deviate from each other 
by more than 5 %. The weight deviation of 
both Capsule 1 and 2 fell within this range at 
time 0 and up to 12 weeks when stored at 
the three test conditions (25 °C + 60% RH; 
30 °C + 60 % RH; 40 °C + 75% RH). 
However, there were significant differences 
(p < 0.05) between the disintegration times 
of Capsule 1 and 2 initially and after storage; 
but the disintegration time was still within the 
30 min required by the BP and USP. 
Throughout, the disintegration time of 
Formula 2 was consistently longer than that 
of Formula 1. This could be because of the 
superior disintegration properties of 
microcrystalline cellulose and the difference 
in particle size between Avicel, ~100 µm, 
and Starch 1500, ~ 52 µm17,18. The smaller 
starch particles filled the capsules more 
densely forming a much denser plug that 
took longer to disintegrate.  
Loss on drying measurements showed that 
Capsule 1 had an average percentage 
weight loss of 4-5 % while Capsule 2 had a 
percentage loss of 8-10 %. This may be 
because starch is slightly more hygroscopic 
than microcrystalline cellulose17. However, 
the moisture uptake of both formulas was 
within the limits set by major pharmacopoeia 
and did not influence the sennoside content 
of the capsules. The USP15 states that 
sennoside tablets should not contain less 
than 90 % and not more than 110 % 
sennosides. Since there are no limits for 
sennoside capsules, the limits for the tablets 
were used to evaluate the content of the 
capsules. Both Capsule 1 and 2, Figure 3, 
complied with this specification under all the 
conditions for which the capsules were 
tested. 
Potential problems with the availability of the 
sennosides from the capsules were tested 
by measuring the dissolution rate of the drug 
from the capsules. The limits for the 
dissolution of sennoside tablets according to 
the USP state that not less than 75% of the 
labelled amount should be dissolved after 
120 min. These limits were also used for the 
sennoside capsules. All of the dissolution 
profiles fell within the limits specified by the 
USP for sennoside tablets because the 
dissolution of both formulas were more than 
75% of the labelled amount of sennoside 
dissolved within 60 min. As an example the 
initial dissolution profiles for capsules 1 and 
2 compared to that obtained after storage at 
40 °C for 12 weeks are given in Figures 4. 
The lag time for the dissolution from Capsule 
2 (Figure 4) correlated with the differences in 
disintegration times. Comparison of the 
dissolution profiles for the two formulas at 25 
ºC, 30 ºC and 40 ºC showed that the 
sennosides seem to be completely dissolved 
after 15 min from Capsule 1 and within 45 
min from Capsule 2. To quantify this 
difference, the dissolution profiles were 
compared using a mathematical method to 
calculate the similarity between two 
dissolution profiles19. 
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The similarity factor (f2) is a logarithmic 
reciprocal square root transformation of the 
average of the squared vertical distances 
between the test (T) and reference (R) mean 
dissolution values at each dissolution time 



















Figure 3: Initial assay results for the sennoside products compared to the assay results after being 























Capsule 1 (12 weeks 40ºC)
Capsule 2 (12 weeks 40ºC)
 
Figure 4: Initial dissolution profiles for the sennoside capsule formulations compared to the 
dissolution profiles after being stored for 12 weeks at 40°C + 75 % RH 
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in the percent (%) dissolution between the 
two curves. Values of f2 between 50 and 100 
indicate sameness of the two dissolution 
profiles19. Comparison of the dissolution 
profiles of Capsule 1 constantly produced f2 
values below 50 which is an indication of 
dissimilarity between the initial profile of this 
formula and the profile both at 25ºC and 
40ºC after 12 weeks. The f2 values 
calculated for Capsule 2 at all the test 
conditions were between 50 and 100 and the 
dissolution profiles were therefore not 
significantly different. 
Formulation of Sennoside Tablets 
The majority of pharmaceutical dosage 
forms are marketed as tablets. To the 
consumer tablets offer the convenience of 
administration, handling, identification and 
proper dosage; to the manufacturer relative 
low-cost and high speed production. In this 
study one direct compression formula and 
one wet granulation formula were made for 
stability purposes after several trial and error 
batches of a number of different formulas 
were tested. The formulae for sennoside 
tablets are shown in Table 4. Tablets from 
both formulations complied with 
pharmacopeial standards for content (mean: 
96 %; minimum: 93 %; maximum: 105 %), 
weight uniformity, tablet thickness and 
diameter, hardness (mean 59 ± 4.1 N), 
moisture content, and friability. These 
properties did not change significantly after 
storage for 12 weeks at elevated 
temperature and humidity. 
The disintegration times for the wet 
granulated formula (20 min) were 
significantly longer than that of the directly 
compressed formula (10 min) and for the 
granulated tablet formula there was also a 
significant increase (p<0.05) in disintegration 
time after storage at elevated temperatures. 
The longest disintegration time (40 min) was 
measured for tablets stored for 12 weeks at 
40 ºC. This may be due to the fact that PVP, 
used in the formulation, has a high binding 
strength and when kept at higher 
temperatures the binding strength increased 
due to a process known as polymer curing. 
Polymer curing is a process whereby the 
reaction between a polymer and a liquid 
causes the polymer to harden over time18.  
The dissolution profiles for the direct 
compressed formula differed from the wet 
granulated formula. The direct compressed 
formula dissolved more rapidly than the wet 
granulated formula (Figure 5). This 
correlated with the difference in 
disintegration times. The USP states that for 
the dissolution of sennoside tablets, not less 
than 75% of the labelled amount of 
sennosides must be dissolved after 120 min 
and both formulae complied with these limits. 
There were also no significant differences in 
dissolution profiles for the direct compressed 
formula initially and after 6 and 12 weeks. In 
contrast the dissolution of the wet granulated 
tablets decreased with time, being the 
slowest after 12 weeks at 40 ºC, but these 
Table 4: Composition of the two tablet formulations containing 25 mg sennoside A or B per tablet 
Direct compression (% w/w) Wet granulation (% w/w) Function 
Sennoside 15 Sennoside 15 Active ingredient 
Starch 1500 60 Emcompress 40 Filler/diluent 
Avicel PH200 24 Avicel PH100 40 Filler/disintegrant 
Mg Stearate 1 Mg Stearate 1 Lubricant 
  PVP 4 Binder 
  Water Qs Granulating agent 
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dissolution results still complied with the 
limits stated by the USP.  
Comparisons with the initial dissolution 
profile produced f2 values for the direct 
compressed formula of 50 to 100. This 
confirmed that the dissolution profiles for this 
formulation did not change. The f2 values for 
the wet granulated tablets however, differed 
all from the initial profile (f2 < 50). These 
differences correlate well with the differences 
in disintegration time. The f2 values also 
decreased gradually and the tablets stored 
at the highest humidity and highest 
temperature (40 °C + 75% RH) has the 
lowest f2 value (29) when compared to the 
initial dissolution profile. Although these 
differences were significant, all the 
        Table 5: Formula for directly compressed effervescent sennoside tablets 
Ingredient Weight per Tablet (mg) Function 
Sennoside A or B 28 Active ingredient 
Citric acid 980 Acidifier 
NaHCO3 728 Carbonate salt 
Na2CO3 196 Carbonate salt 
Sodium cyclamate 112 Sweetener 
Sodium saccharin 11 Sweetener 
Ginger 39 Flavouring agent 
PEG 6000 85 Lubricant 
PVP 34 Binding agent 
























Tablet 1 (12 weeks 40ºC)
Tablet 2 (12 weeks 40ºC)
 
Figure 5: Initial dissolution profiles for the sennoside tablet formulations (Tablet 1 – direct 
compression; Tablet 2 – wet granulation) compared to the dissolution profiles after being stored for 12 
weeks at 40 °C + 75 % RH 
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dissolution tests complied with the 
dissolution criteria set by the USP for 
sennoside tablets. 
Formulation of Sennoside Effervescent 
Tablets 
Effervescence is defined as the evolution of 
bubbles of gas in a liquid, as the result of a 
chemical reaction when solids dissolve. 
Effervescent mixtures have been known and 
used medicinally for many years. 
Effervescent tablets are convenient, easy to 
use, pre-measured dosage forms that are 
already in solution when ingested. Another 
significant advantage of effervescent tablets 
is that they can be used to mask unpleasant 
flavours and convert solids into liquids for 
easier consumption. In this study, the 
formula in Table 5 was used after trying out 
several batches using trial and error. These 
trial batches had disintegration times that 
were too long, or the powder stuck to the 
punch and die during tableting. 
The effervescent tablets were stored for 12 
weeks at elevated temperatures and relative 
humidity in aluminium tubes containing silica 
gel as a desiccant in the HDPE lids and in 
HDPE containers without silica gel in the lid. 
Tests for loss on drying, hardness and time 
of effervescence were done on the tablets 
stored in these containers, to determine the 
effect of moisture on the tablets. After 12 
weeks the sennoside content of the tablets 
were not significantly different from the initial 
assay and all the tablets complied with the 
USP specification of between 90-110% 
active per tablet. The pH (5.7) of the 
solutions formed after effervescence was 
determined.  It also did not change with time. 
After 12 weeks the tablet weight, tablet 
thickness and diameter, and time for 
effervescence to be completed (2 – 3 min) 
did not change for the tablets stored in 
containers containing the desiccant. 
However, the time for effervescence to be 
completed significantly increased (p<0.05) 
for the tablets stored in containers without a 
desiccant. The time for effervescence to be 
completed increased from an initial value of 
~ 2 min to ~ 5 min after 12 weeks at 40 °C + 
75% RH.  
Conclusion 
The results of the compatibility study showed 
that thermal analysis is useful for the 
determination of reactions between 
sennosides and excipients, especially when 
combined with the quantitative analysis of 
the drug with HPLC. Both DSC and HPLC 
confirmed no incompatibilities in the dry 
mixtures. The only inconsistent results 
between DSC and HPLC were propyl 
paraben and citric acid that showed an 
interaction by HPLC and not by DSC. 
Compatibility evaluation shows that dry 
powder mixtures for filling capsules and for 
direct compression of tablets can thus be 
used to formulate sennosides A & B into 
tablets. Wet granulation can be used to 
formulate tablets and capsules containing 
sennosides, but propyl paraben, sodium 
carbonate, stearic acid, citric acid, PEG, and 
sugar derivatives such as lactose, glucose 
and sorbitol should not be used in these 
formulations. 
Using the results from the compatibility study 
it was possible to compound two sennoside 
capsules which complied with the criteria set 
by the USP for sennoside tablets although 
there were slight differences in the 
dissolution rate, disintegration times, and 
stability. Sennoside tablets were also 
successfully manufactured using both direct 
compression and wet granulation methods. 
The directly compressed formula had a 
faster disintegration time and dissolved more 
quickly. However, the flow properties of the 
wet granulated formula were better, which 
should make it the more preferred method 
for large scale manufacture. Both formulae 
were stable for the 12 weeks tested at 
elevated temperatures up to 40°C + 75% RH 
and should therefore be viable for 
compounding sennoside tablets. In addition 
to capsules and tablets, effervescent tablets 
that dissolved quickly and remained stable 
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for 12 weeks if stored with desiccant in the 
containers were also successfully 
compounded. These tablets would be ideally 
suited for treating patients that have difficulty 
with swallowing tablets and capsules. 
Acknowledgment 
The authors would like to acknowledge the 
financial assistance from the National 




1. Whorton JC. The phenolphthalein follies: purgation 
and the pleasure principle in the early twentieth 
century. Pharmacy in history 1993; 35: 2-24. 
2. Toman KG. Gastrointestinal and liver drugs. In: 
Gennaro AR, Popovich NG, Der Marderosian 
AH, Schaare RL, Hanson GR, Schwartz JB, 
Medwick T, White HS (eds.). Goodman and 
Gillman’s: The Pharmacological Basis of 
Therapeutics. 20th ed. New York, USA: 
Lippincott, Williams and Wilkins, 2000, pp 1229-
34. 
3. Pietrusko RG. Use and abuse of laxatives. Am J 
Hosp Pharm 1997; 34: 291-300. 
4. Edwards C, Stillman P. Constipation. Pharm J 
1993; 251: 53-5. 
5. Artymowics RJ, Childs AL, Paolini L. 
Phenolphthalein-induced toxic epidermal 
necrolysis. Annal Pharm 1997; 31: 1157-9. 
6. Cummings JH, Sladen GE, James OFW, Sarner 
M, Misiewicz JJ. Laxative induced diarrhoea: A 
Continuing medical problem. Br Med J 1974; 23: 
537-541. 
7. Dunnick JK, Hailey JR. Phenolphthalein exposure 
causes multiple carcinogenic effects in 
experimental model systems. Can Res 1996; 
56: 4922-6. 
8. Dunnick JK, Hardisty JF, Herbert RA, Seely JC, 
Furedi-Machacek EM, Foley JF, Lacks GD, 
Stasiewicz S, French JE. Phenolphthalein 
induces thymic lymphomas accompanied by 
loss of the p53 wild type allele in heterozygous 






9. Tice RR, Furedi-Machacek M, Satterfield DD, 
Udumudi A, Vasquez M, Dunnick JK. 
Measurement of micronucleated erythrocytes 
and DNA damage during chronic ingestion of 
phenolphthalein in transgenic female mice 
heterozygous for the p 53 gene. Environ Mol 
Mutagen 1998; 31: 113-24. 
10. Food and Drug Administration. Laxative drug 
products for over the counter use; proposed 
amendment to the tentative final monograph. 
Federal Register 1997; 62:46223-46227. 
[Available on Internet: http://www.access. 
gpo.gov/su_docs/aces/aces140.html]. 
11. Collins BJ, Grizzle TB, Dunnick JK. Toxicokinetics 
of phenolphthalein in male and female rats and 
mice. Toxicol Sci 2000; 56: 271-81. 
12. Registrar of Medicines. Ban on phenolphthalein 
and products containing phenolphthalein. South 
African Government Gazette 2002; No. 192, 22 
Feb. 
13. Wells J. Pharmaceutical preformulation: The 
physicochemical properties of drug substances. 
In: Aulton ME (ed). Pharmaceutics the Science 
of Dosage Form Design, 2nd ed. London, 
England: Churchill Livingstone, 2002, pp 113-
38. 
14. Muffat F, Bernard P, Sabot JF. Determination of 
sennosides A and B in senna extracts by high-
performance liquid chromatography. J Chrom A 
1986; 396: 261-4. 
15. United States Pharmacopeia (USP) 24. Rockville, 
MD, USA: United States Pharmacopeial 
Convention, 2000, 2569p. 
16. British Pharmacopoeia (BP). London, England: Her 
Majesty's Stationary Office, 1998, 1281p. 
17. Kibbe AH (ed). Handbook of Pharmaceutical 
Excipients, 3rd ed. Washington, DC, USA: 
American Pharmaceutical Association, 2000, 
665p. 
18. Ansel HC, Allen LV, Popovich NG. Pharmaceutical 
dosage forms and drug delivery systems, 7th ed, 
New York, USA: Lippincott, Williams and 
Wilkins, 1999, 595p. 
19. Moore JW, Flanner HH. Mathematical comparison 
of dissolution profiles. Pharm. Technol 1996; 20: 
64-74. 
  
